ArticleResearch in pharmaceutical sciences2025
The role of gelatin and collagen in cell viability and osteogenic potential of an injectable chitosan-based scaffold containing LL37 peptide.
Article in Research in pharmaceutical sciences, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and purpose: LL37 peptide is a human antimicrobial peptide with potential application in bone tissue engineering through the stimulation of cell proliferation and osteogenesis. The current study aimed to fabricate chitosan/gelatin/glycerophosphate (CTS/G/GP) and chitosan/collagen/glycerophosphate (CTS/C/GP) thermosensitive hydrogels loaded with LL37 and compared their ability to support cell growth, proliferation, and osteogenesis. Experimental approach: The hydrogel systems were prepared by the physical mixture of chitosan, gelatin, collagen, and GP at the concentrations of 2.5, 1, 1, and 10% w/v, respectively. LL37 was added at a fixed concentration of 1 μg/mL of the hydrogels. The viscosity, friability, release properties, and biological experiments were evaluated based on standard procedures. Findings/Results: The viscosity of CTS/C/GP increased to 7000 cP at 35 °C in 100-120 s, while for CTS/G/GP, the viscosity and gelation time were recorded as 14000 cP and 30 s, respectively. The friability percent for CTS/G/GP after 72 h was reported as 28%, which was significantly lower than that of 38% for CTS/C/GP. LL37 was released during 8 h from both scaffold systems, and it did not demonstrate any significant differences between the hydrogel systems. Cell viability and alkaline phosphatase activity revealed that the incorporation of LL37 in the hydrogels could accelerate cell proliferation compared to empty scaffolds, and it was higher in gelatin-containing scaffolds. Conclusion and implications: LL37 was successfully loaded into both hydrogel systems and demonstrated the ability to accelerate cell proliferation and differentiation compared to the empty scaffold.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.